You are here: Industry Insights > Samsung Bioepis

News List

Samsung Biologics to buy out Biogen's stake in Samsung Bioepis CPhIonline
January 29, 2022
Samsung Biologics has reached an agreement for the buyout of Biogen’s stake in the Samsung Bioepis joint venture for USD $2.3 billion.
Samsung Biologics to acquire Biogen’s stake in Samsung Bioepis for $2.3bn Pharmaceutical-Technology
January 29, 2022
Biogen is eligible to receive up to $50m from Samsung Biologics on meeting some commercial milestones.
o9 Solutions to supply AI-powered IBP platform to Samsung Bioepis expresspharma
February 02, 2021
o9 Solutions, a AI-powered IBP platform provider has announced that it would supply its next-generation platform to Samsung Bioepis bolstering the management of its biopharmaceutical product manufacturing and supply chain.
Samsung Bioepis Opens New Headquarters contractpharma
January 26, 2021
The 52,000-square-foot campus to become the hub of Samsung Bioepis’ drive for accelerated development of next-gen biologic medicines.
Samsung Bioepis, Biogen Announce FDA Filing Acceptance of Lucentis Biosimilar americanpharmaceuticalreview
December 04, 2020
Samsung Bioepis and Biogen announced the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for SB11, a proposed biosimilar referencing Lucentis® (ranibizumab).
FDA to review Samsung Bioepis and Biogen’s biosimilar SB11 pharmaceutical-technology
November 20, 2020
The US Food and Drug Administration (FDA) has accepted Samsung Bioepis and Biogen’s biologics licence application to review the use of SB11 as a biosimilar referencing Lucentis (ranibizumab).
EMA accepts filing for Biogen/Samsung Bioepis’ Lucentis biosimilar pharmatimes
October 10, 2020
The European Medicines Agency (EMA) has accepted for review the marketing authorisation for Biogen and Samsung Bioepis’ biosimilar referencing Genentech's Lucentis (ranibizumab).
Samsung Bioepis secures positive CHMP opinion for Aybintio pharmaceutical-technology
June 28, 2020
Korean biopharmaceutical firm Samsung Bioepis has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for Aybintio, a biosimilar to Avastin (bevacizumab).
Samsung Bioepis, Merck Launch Trastuzumab Biosimilar americanpharmaceuticalreview
April 16, 2020
Samsung Bioepis announced ONTRUZANT® (trastuzumab-dttb), a biosimilar of the reference biologic medicine HERCEPTIN® (trastuzumab) for the treatment of ...
Samsung Bioepis Announces FDA Approval of 420 mg Multi-dose Vial of ONTRUZANT americanpharmaceuticalreview
March 25, 2020
Samsung Bioepis announced the U.S. Food and Drug Administration (FDA) has approved a 420 mg multi-dose vial of ONTRUZANT® (trastuzumab-dttb).

Previous page 1 2 Next page